

This is confidential information of the GSK group of companies. This document is the presented version of the publication on which you are an author and its content cannot be changed after approval in Datavision. This document is for your personal use only and should not be used for other purposes nor shared further in any circumstances (this could generate a violation of congress copyright). Presentations and posters are not peer-reviewed and should preferably not be used for citation. The preferred reference to be used for citation is the published abstract printed in the abstract book or on congress website. Any material from the associated presentations may not be used without permission. Premature disclosure of unpublished material can result in refusal of publications by journals and congresses. If authors or other persons wish to use any part of the presentations, a request should be sent to GSK (ingrid.b.leal@gsk.com).

PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY TO ASSESS THE BURDEN OF HERPES ZOSTER DISEASE IN THE EYE: BASELINE RESULTS OF INITIAL PATIENTS

Laura T. Pizzi^{1*}, Benjamin Leiby², David Chu³, Emily W. Gower⁴, Haresh Ailani⁵, Joseph P. Shovlin⁶, Katherine M. Prioli¹, Soham Shukla¹, Brandon J. Patterson⁷, Deborah Rausch⁷, Philip O. Buck⁷, Ann P. Murchison⁸

¹Rutgers University, Piscataway, NJ, USA; ²Thomas Jefferson University, Philadelphia, PA, USA; ³Metropolitan Eye Research and Surgery Institute, Palisades Park, NJ, USA; ⁴Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA; ⁵Eye Consultants of Northern Virginia, Springfield, VA, USA; ⁶Northeastern Eye Institute, Scranton, PA, USA; ⁷GSK, Philadelphia, PA, USA; ⁸Wills Eye Hospital, Philadelphia, PA, USA; *Presenting author: Laura Pizzi, laura.pizzi@rutgers.edu

BACKGROUND


- With about 1 million cases of herpes zoster in the US annually, approximately 10-20% are complicated by herpes zoster ophthalmicus (HZO),¹ many of which have ocular involvement that can lead to vision threatening complications.²
- Objectives: describe the frequency, duration, and impact of HZO complications; and vision-specific health-related quality of life and depressive symptoms in acute HZO patients.

METHODS

- This ongoing, 1-year, prospective, multicenter (6 major US ophthalmology practices), observational cohort study aims to recruit 300 patients; herein, we report diagnoses and baseline patient-reported outcomes for the first 13 patients.

RESULTS

Patients' ocular diagnoses and self-reported pain and symptoms




Other ocular diagnosis: n=6; other herpes zoster ophthalmicus disease: n=3; other ocular problems: n=9. HZ, herpes zoster. Patients may have more than one ocular symptom/diagnosis, thus the total may be >13. Symptoms are not mutually exclusive or specific to one eye.

CONCLUSIONS

- This study represents initial patients' data from the first large-scale effort to quantify HZO burden.
- These preliminary data show that HZO commonly has an impact on the eye, including pain and other self-reported outcomes.
- Ultimately, the findings may be used to help develop a formal patient-reported symptom scale for use in research and clinical practice.


Patient selection & study design



Demographic characteristics

- 11/13 Women
- 13/13 Medical insurance (10/13 Medicare)
- 9/13 Retired
- 7/13 College graduates (or other degree)
- Mean age: 71 years

Patients' self-reported outcomes



For NEI-VFQ-25 (National Eye Institute 25-item Visual Function Questionnaire), only mean scores <75 are shown; scores range: 0 – 100. ZBPI (Zoster Brief Pain Inventory) scores range: 0 – 10. PHQ-8 (eight-item Patient Health Questionnaire depression scale) scores range: 0 – 24. Data is represented as mean score ± standard deviation.



- Herpes zoster ophthalmicus is associated with eye pain and other eye symptoms.
- Herpes zoster ophthalmicus may affect quality of life.

Funding: GlaxoSmithKline Biologicals SA (GSK study identifiers: 209235/HO-17-17967)

